Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice

PD-1/PD-L1 inhibitors

(2015) Joel Sunshine et al.   CURRENT OPINION IN PHARMACOLOGY

Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.

(2015) Harpreet Singh et al.   JOURNAL OF CLINICAL ONCOLOGY

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

(2015) T. Kouo et al.   Cancer Immunology Research

A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates

(2014) Caroline Jochems et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation

(2014) Emanuela I. Sega et al.   PLoS One

Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo

(2014) Nicholas M. Durham et al.   PLoS One

Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy

(2014) Stefanie J Mandl et al.   Journal for ImmunoTherapy of Cancer

A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer

(2013) Michael A. Morse et al.   ANNALS OF SURGERY

Immune Modulation in Cancer with Antibodies

(2013) David B. Page et al.   Annual Review of Medicine

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer

(2013) J. L. Gulley et al.   Cancer Immunology Research

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

(2012) Ravi A Madan et al.   LANCET ONCOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization

(2012) Lukas Baitsch et al.   PLoS One

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines

(2012) Ravi A. Madan et al.   SEMINARS IN ONCOLOGY

Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells

(2011) Stefanie J. Mandl et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection

(2011) Noah S Butler et al.   NATURE IMMUNOLOGY

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

A flow cytometry-based immuno-titration assay for rapid and accurate titer determination of modified vaccinia Ankara virus vectors

(2010) Zengji Li et al.   JOURNAL OF VIROLOGICAL METHODS

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

(2009) Ravi A Madan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells

(2009) J. F. Grosso et al.   JOURNAL OF IMMUNOLOGY

LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis

(2009) C. J. Workman et al.   JOURNAL OF IMMUNOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer

(2008) C A Crane et al.   ONCOGENE

Selective expansion of a subset of exhausted CD8 T cells by  PD-L1 blockade

(2008) S. D. Blackburn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA